Fondaparinux dosage forms and strengths: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:


'''Single-dose''', prefilled syringes containing either '''2.5 mg, 5 mg, 7.5 mg, or 10 mg''' of fondaparinux.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>
'''Single-dose''', prefilled syringes containing either '''2.5 mg, 5 mg, 7.5 mg, or 10 mg''' of fondaparinux.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==
Line 11: Line 15:


{{FDA}}
{{FDA}}
 
[[Category: Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 20:08, 3 March 2014

Fondaparinux
Arixtra® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Dosage Forms And Strengths

Single-dose, prefilled syringes containing either 2.5 mg, 5 mg, 7.5 mg, or 10 mg of fondaparinux.[1]



References

  1. "ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]".

Adapted from the FDA Package Insert.